Related references
Note: Only part of the references are listed.Economic burden of rheumatoid arthritis: a systematic review of literature in biologic era
Ping-Hsuan Hsieh et al.
ANNALS OF THE RHEUMATIC DISEASES (2020)
Two-year cost effectiveness between two gradual tapering strategies in rheumatoid arthritis: cost-utility analysis of the TARA trial
Elise van Mulligen et al.
ANNALS OF THE RHEUMATIC DISEASES (2020)
Indirect Costs of Rheumatoid Arthritis Depending on Type of Treatment-A Systematic Literature Review
Bogdan Batko et al.
INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH (2019)
Clinical management of seronegative and seropositive rheumatoid arthritis: A comparative study
Sang-Tae Choi et al.
PLOS ONE (2018)
Comparative Price Analysis of Biological Products for Treatment of Rheumatoid Arthritis
Manoela Manova et al.
FRONTIERS IN PHARMACOLOGY (2018)
2016 update of the EULAR recommendations for the management of early arthritis
Bernard Combe et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
The prevalence of ACPA is lower in rheumatoid arthritis patients with an older age of onset but the composition of the ACPA response appears identical
Debbie M. Boeters et al.
ARTHRITIS RESEARCH & THERAPY (2017)
Best cost-effectiveness and worker productivity with initial triple DMARD therapy compared with methotrexate monotherapy in early rheumatoid arthritis: cost-utility analysis of the tREACH trial
Pascal H. P. de Jong et al.
RHEUMATOLOGY (2016)
Systematic overview of cost-effectiveness thresholds in ten countries across four continents
Ruth Schwarzer et al.
JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH (2015)
Randomised comparison of initial triple DMARD therapy with methotrexate monotherapy in combination with low-dose glucocorticoid bridging therapy; 1-year data of the tREACH trial
P. H. de Jong et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
The global burden of rheumatoid arthritis: estimates from the Global Burden of Disease 2010 study
Marita Cross et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
EULAR definition of erosive disease in light of the 2010 ACR/EULAR rheumatoid arthritis classification criteria
Desiree van der Heijde et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
Cost-effectiveness of biologic treatment for rheumatoid arthritis in clinical practice: An achievable target?
Vittorio Modena et al.
AUTOIMMUNITY REVIEWS (2013)
Economic aspects of treatment options in rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis
Monika Schoels et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
Cost-Utility Analysis of Treatment Strategies in Patients With Recent-Onset Rheumatoid Arthritis
Wilbert B. van den Hout et al.
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH (2009)
Use of risk stratification to target therapies in patients with recent onset arthritis; design of a prospective randomized multicenter controlled trial
Susanne J. J. Claessen et al.
BMC MUSCULOSKELETAL DISORDERS (2009)
Cost of illness in rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and systemic lupus erythematosus in Germany
D. Huscher et al.
ANNALS OF THE RHEUMATIC DISEASES (2006)
Systematic review of studies of productivity loss due to rheumatoid arthritis
W Burton et al.
OCCUPATIONAL MEDICINE-OXFORD (2006)
Health, absence, disability, and presenteeism cost estimates of certain physical and mental health conditions affecting US employers
RZ Goetzel et al.
JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL MEDICINE (2004)
Costs of rheumatoid arthritis in Germany:: a micro-costing approach based on healthcare payer's data sources
J Ruof et al.
ANNALS OF THE RHEUMATIC DISEASES (2003)
How to diagnose rheumatoid arthritis early - A prediction model for persistent (erosive) arthritis
H Visser et al.
ARTHRITIS AND RHEUMATISM (2002)
Share Paper
